🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  2. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  3. AG-348

    Agios Netherlands B.V.

    Thalassemia

    phase 2 small molecule active

    1 trial

  4. AG10

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy

    phase 2 small molecule active

    1 trial

  5. AG10

    BridgeBio Oncology Therapeutics

    Familial ATTR-CM (ATTRm-CM, or FAC)

    phase 2 small molecule completed

    1 trial

  6. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

  7. AIR DNase™

    Protalix BioTherapeutics

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  8. AK0529

    Shanghai University of Traditional Chinese Medicine

    RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

    phase 2 small molecule completed

    1 trial

  9. AKCEA-ANGPTL3-LRX

    IONIS PHARMACEUTICALS INC

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  10. AKCEA-ANGPTL3-LRx

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 2 small molecule completed

    1 trial

  11. AKCEA-ANGPTL3-LRx

    IONIS PHARMACEUTICALS INC

    Familial Partial Lipodystrophy

    phase 2 small molecule completed

    1 trial

  12. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  13. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  14. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  15. ALEXAN, 50 MG/ML, ROZTWÓR DO INFUZJI, Liposomal Annamycin

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  16. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 2 small molecule active

    1 trial

  17. ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  18. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  19. ALKS 2680, ALKS 2680, Placebo to match ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Idiopathic Hypersomnia (IH)

    phase 2 small molecule active

    1 trial

  20. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  21. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  22. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  23. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  24. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources